Enterprise Value
974.7M
Cash
371M
Avg Qtr Burn
N/A
Short % of Float
18.11%
Insider Ownership
19.39%
Institutional Own.
90.63%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
WAKIX® (pitolisant) Details Narcolepsy (Adult) | Approved Quarterly sales | |
WAKIX® (pitolisant) Details Narcolepsy | sNDA Submission | |
WAKIX® (pitolisant) Details EDS in Idiopathic Hypersomnia
| Phase 3 Update | |
WAKIX® (pitolisant) Details Genetic disorder, Rare genetic disease, Prader-Willi syndrome, Excessive daytime sleepiness | Phase 3 Initiation | |
WAKIX® (pitolisant) Details Muscle degeneration, Muscle weakness, Myotonic Dystrophy Type 1 | Phase 2 Data readout | |
ZYN002 Details no known indication | Phase 2 Data readout |